公司信息

恒瑞医药高薪诚聘 恒瑞医药（股票代码600276）是一家以生产和销售抗肿瘤药、手术用药、心血管及内分泌药物为主的创新型制药企业，国家定点麻醉药品生产厂家。2000年在沪市上市，2010年在医药上市企业最具竞争力二十强评选中，公司名列第一，股票市值位列a股医药上市企业前三名。 公司建有***企业技术中心，***博士后科研工作站，是国家重点高新技术企业，国家“863”计划成果产业化基地，国家火炬计划新医药研究开发及产业化基地的骨干企业之一。 恒瑞医药是国内最大的抗肿瘤药物研究和生产基地，先后打造了艾恒、艾素、艾力等众多知名品牌，市场份额在国内排名第一；此外，公司生产的手术用药、消化道用药所占市场份额居国内行业前列。2008年，国家科技部组织实施“重大新药创制”专项，恒瑞医药以企业第一名的评分率先入选重大专项新药孵化器基地。2010年被科技部评定为“中国抗肿瘤药物技术创新产学研联盟”的牵头单位。2010年被国家工信部评为国内***研发产品线十佳第一名。2009年8月，公司自主研发的用于治疗Ⅱ糖尿病的一类新药瑞格列汀在美国获批进入一期临床，这是我国化学制药行业首次在美国进行创新药的临床试验，下一步公司还将向美国申请抗肿瘤创新药进行临床实验。 恒心致远，瑞颐人生。恒瑞人一直秉承“为人类创造健康生活”的理念，为铸就百年恒瑞而不断努力奋斗。 恒瑞医药在美国、上海和连云港、成都均设立研究中心，并在北京设立临床医学部，拥有各类高层次研发人员700多名，其中有400名博士、硕士及海归人士。 jiangsu hengrui medicine is a fully integrated pharmaceutical company with r & d, manufacturing, and sales of oncology, cv, anti-infective, surgical drugs and contrast media.state designated manufacturer of narcotic drugs . hengrui medicine has listed in shanghai securities exchange in 2000; in 2010, ranked first among 20 of the most competitive public companies in the pharma sector in china; ranked as top three in the stock market value of a gu of chinese public pharmaceutical companies.designated head liaison by ministry of chinese science and technology for the china research alliance of innovation in anti-neoplastic drugs. hengrui medicine has two state-of-art r&d centers in shanghai and lianyungang. its medical department is located in shanghai. in addition, there are four oversee r&d facilities in us and sweden. currently over 600 scientists are employed, including 150 phd, ms, and oversee returnees. retgliptin, a dpp-4 inhibitor, was tested in phase 1 in the us in august, 2009. this was the first entry of an nme created by a chinese pharmaceutical company in the us for clinical evaluation. a series of nmes in the area of oncology& diabetes are being prepared for clinical tests on a global scale. a fully integrated, globally-competitive pharmaceutical company capable of delivering 1-2 nmes annually to patients with unmet medical needs.